Crossmark Global Holdings Inc. Buys 4,741 Shares of argenx SE (NASDAQ:ARGX)

Crossmark Global Holdings Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX) by 100.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,462 shares of the company’s stock after buying an additional 4,741 shares during the period. Crossmark Global Holdings Inc.’s holdings in argenx were worth $5,130,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Blue Trust Inc. increased its holdings in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares during the last quarter. J.Safra Asset Management Corp increased its stake in shares of argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares in the last quarter. GAMMA Investing LLC raised its position in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the period. Point72 Hong Kong Ltd purchased a new stake in shares of argenx during the 2nd quarter valued at approximately $76,000. Finally, Cromwell Holdings LLC boosted its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Trading Down 1.2 %

Shares of ARGX stock opened at $588.94 on Tuesday. The company’s fifty day moving average price is $548.48 and its 200-day moving average price is $476.70. The stock has a market cap of $35.22 billion, a PE ratio of -669.25 and a beta of 0.61. argenx SE has a 12 month low of $327.73 and a 12 month high of $611.22.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter last year, the firm earned ($1.25) earnings per share. On average, sell-side analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JMP Securities boosted their target price on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Truist Financial increased their price objective on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. upped their price target on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Citigroup raised their price objective on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $615.50.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.